Poster Schedule

1:15 PM – 2:15 PM EEST

P-332: Challenge accepted: copy number detection by digitalMLPA on small DNA quantities and low tumour content

1:15 PM – 2:15 PM EEST

P-333: Multi-omic analysis of multiple myeloma subtypes reveals epigenetic programs of high-risk disease

1:15 PM – 2:15 PM EEST

P-334: Fluorescence in situ hybridization (FISH) t(11;14) testing practices over time in patients with newly diagnosed multiple myeloma (MM) in the USA in the Flatiron Health database

1:15 PM – 2:15 PM EEST

P-335: Small nucleotide, copy number and structural variants cooperate to hijack driver genes in extramedullary progression of myeloma

1:15 PM – 2:15 PM EEST

P-336: Prognostic relevance of NOTCH-driven matrisome-associated genes in multiple myeloma

1:15 PM – 2:15 PM EEST

P-337: The germinal center origin and progression of MM is captured by 83 Vk*MYC MM transplantable lines that share overlapping genomic diversity with human disease

1:15 PM – 2:15 PM EEST

P-338: Differential DNA Mutation Profiles in Multiple Myeloma Patients: Implications of PET/CT Findings

1:15 PM – 2:15 PM EEST

P-339: Longitudinal Genetically Detectable Minimal Residual Disease by Interphase Fluorescence in Situ Hybridization Confers a Poor Prognosis in Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-340: Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma

1:15 PM – 2:15 PM EEST

P-341: Use of Optical Genome Mapping in the Cytogenetic Diagnosis of Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-342: Genomic Profiling of Treated High-Risk Smoldering Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-343: Evaluation of single nucleotide variants in BRCA1, CDKN1A, TP53BP, and XRCC1 in multiple myeloma patients undergoing hematopoietic stem cell transplantation. Association with clinical outcomes

1:15 PM – 2:15 PM EEST

P-344: Multiomics profiling of extramedullary multiple myeloma tumors and their microenvironment

1:15 PM – 2:15 PM EEST

P-345: Connecting 1q amplification and PHF19 expression in high-risk myeloma clones

1:15 PM – 2:15 PM EEST

P-346: Internal Tandem Duplications of the BCMA Transmembrane Domain are Common in Hyperdiploid Multiple Myeloma and Associated with Constitutive NF-kB Signaling

1:15 PM – 2:15 PM EEST

P-347: Longitudinal Profiling Identifies Genetic Mechanisms of Resistance to Four Different Drug Classes in a t(4;14) Positive Patient

1:15 PM – 2:15 PM EEST

P-348: ADAR1-regulated cytoplasmic dsRNA-immune sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

1:15 PM – 2:15 PM EEST

P-349: A retrospective assessment of biologically relevant genomic perturbations and variants of unknown significance in a cohort of plasma cell disorder at our institution; a single center experience

1:15 PM – 2:15 PM EEST

P-350: Single cell Analysis identifies new insights into the development of venetoclax resistant in Multiple Myeloma patients

1:15 PM – 2:15 PM EEST

P-351: Are genomic lesions of Cereblon pathway genes sufficient to explain clinical relapses from IMiD-based treatment in multiple myeloma (MM)?

1:15 PM – 2:15 PM EEST

P-352: Enhanced expression of DNp73 promotes drug resistance and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways

1:15 PM – 2:15 PM EEST

P-353: In vitro functional characterization of a multiple myeloma
susceptibility locus

1:15 PM – 2:15 PM EEST

P-354: Whole genome sequencing reveals significant genetic admixture in multiple myeloma patients, impacting assessment of etiology

1:15 PM – 2:15 PM EEST

P-355: A novel genomewide RNA-Targeting CRISPR/Cas13 Screen Identifies a Plasma Cell-Specific long non-coding RNA (LncRNA) Essential for Myeloma Cell Growth

1:15 PM – 2:15 PM EEST

P-356: EFFECT OF AMPLIFICATION OR GAIN OF 1Q21 IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH DARATUMUMAB

1:15 PM – 2:15 PM EEST

P-357: Individualized Risk in Newly Diagnosed Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-358: Myeloma at a younger age presents with distinctive clinical and molecular features

1:15 PM – 2:15 PM EEST

P-359: Non-Paraskeletal Extramedullary Disease Is Associated with high rates of high risk cytogenetic alterations and has a distinct transcriptional profile

1:15 PM – 2:15 PM EEST

P-360: Exploring the role of the Polycomb Repressive Complex 2 in High-Risk Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-361: Genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma

1:15 PM – 2:15 PM EEST

P-362: ID2 acts as a novel tumor suppressor in MM by inhibition of TCF3 transcriptional activity

1:15 PM – 2:15 PM EEST

P-363: Mitochondrial Protease ClpP is a Novel Immunogenic Vulnerability in Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-364: Novel FKBP12 targeting PROTACs enhances BMP-induced apoptosis in multiple myeloma

1:15 PM – 2:15 PM EEST

P-365: Genetic Profiling and Drug Response Analysis in Multiple Myeloma: Insights for Personalized treatment approaches.

1:15 PM – 2:15 PM EEST

P-366: Signaling Pathway Data Analytics of Nephropathy and Neuropathy from Drug Toxicities in Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-367: High-risk cytogenetic abnormalities in Multiple Myeloma: PETHEMA-GEM experience.

1:15 PM – 2:15 PM EEST

P-368: Deep learning-based classifier for malignant plasma cell identification from single-cell RNA-seq data.

1:15 PM – 2:15 PM EEST

P-369: SINGLE CELL MULTI-OMIC CORRELATION OF SINGLE NUCLEOTIDE VARIANTS, COPY NUMBER VARIATION AND SURFACE EPITOPES FOR CLONAL PROFILING OF MYELOMA

1:15 PM – 2:15 PM EEST

P-370: CoMMsol: a machine learning model for outcome-specific Copy Number Alterations’ clonality cut-offs definition in Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-371: Mutant-specific pharmacological inhibition of KRAS in multiple myeloma and functional genomics studies to identify mechanisms regulating myeloma cell response vs. resistance to KRAS inhibition.

1:15 PM – 2:15 PM EEST

P-372: Transcriptomic expression of BMP-2, BMP-6 and Smad6 genes in newly diagnosed and relapsed multiple myeloma patients

1:15 PM – 2:15 PM EEST

P-373: Functional genomics of genes residing in the minimally deleted chromosome 17p13 region in multiple myeloma: therapeutic implications

1:15 PM – 2:15 PM EEST

P-374: Stratifying Multiple Myeloma Patients for Personalized Therapy Based on TP53 Mutation, Deletion, and Drug Response Profiles

1:15 PM – 2:15 PM EEST

P-375: Unraveling Signaling Pathways in Multiple Myeloma Cardiovascular Toxicities from Pharmacovigilance and Pharmacogenomics Data Mining

1:15 PM – 2:15 PM EEST

P-376: Genomic and transcriptional profiling stratifies myeloma models into two clusters with distinct risk signatures and drug responses

1:15 PM – 2:15 PM EEST

P-377: CD38 targeting in Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-378: Longitudinal antibody and T-cell kinetics over four doses of COVID-19 vaccination and predictors of poor response in patients with multiple myeloma.

1:15 PM – 2:15 PM EEST

P-379: Variable humoral and cellular responses to SARS-CoV-2 Bivalent booster vaccination in patients with Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-380: Immunological Aging Is Associated with Worse Clinical Outcome in Elderly Newly Diagnosed Multiple Myeloma Patients

1:15 PM – 2:15 PM EEST

P-381: Mezigdomide (CC-92480) activates innate and adaptive immune populations in the bone marrow microenvironment of heavily pre-treated multiple myeloma patients

1:15 PM – 2:15 PM EEST

P-382: Dysregulations of the immune tumor microenvironment in multiple myeloma

1:15 PM – 2:15 PM EEST

P-383: A 16-gene signature reflecting tumor microenvironment predicts the risk of multiple myeloma patients treated by bortezomib-based therapies

1:15 PM – 2:15 PM EEST

P-384: EXPLOITING FIBER-RICH DIET TO PERTURB THE MICROBIOTA-IMMUNE AXIS AND THWART MULTIPLE MYELOMA PROGRESSION

1:15 PM – 2:15 PM EEST

P-385: Single cell RNA sequencing reveals activated translation machinery in memory T cells among exceptional responders to lenalidomide

1:15 PM – 2:15 PM EEST

P-386: A high risk of progression from smoldering to symptomatic multiple myeloma was predicted by bone marrow and circulating gamma delta T cells.

1:15 PM – 2:15 PM EEST

P-387: Bone marrow immune composition reflects multiple myeloma evolution and influences patients’ outcome

1:15 PM – 2:15 PM EEST

P-388: An IL-1β driven neutrophil-stromal cell axis fosters a BAFF-rich tumor-supportive bone marrow environment in multiple myeloma patients

1:15 PM – 2:15 PM EEST

P-389: Progression to Myeloma reflects accelerating immunosenescence, loss of tumour MHC class I, and tumour growth-associated inflammation

1:15 PM – 2:15 PM EEST

P-390: The differentiation and expansion of T cell clonotypes in the bone marrow following ASCT: insights from the Phase 2 CARDAMON study

1:15 PM – 2:15 PM EEST

P-391: Checkpoint inhibitor PD-1H/VISTA mediates its effects on osteoclast cytoskeleton in myeloma bone disease via c-Src/Rac1 signaling

1:15 PM – 2:15 PM EEST

P-392: Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with Daratumumab-Len-Dex

1:15 PM – 2:15 PM EEST

P-393: COVID-19 vaccine acceptance/hesitancy and influence on infection in patients with multiple myeloma: A national-wide multicenter survey in China

1:15 PM – 2:15 PM EEST

P-394: Proteomic Analysis to Discover Bone Marrow Plasma Biomarkers Predicting Outcome Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients

1:15 PM – 2:15 PM EEST

P-395: THE GUT MICROBIOTA CHANGES DURİNG MULTIPLE MYELOMA TREATMENT

1:15 PM – 2:15 PM EEST

P-396: Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma

1:15 PM – 2:15 PM EEST

P-397: Polyclonal immunoglobulin recovery in myeloma patients receiving maintenance after autologous hematopoietic stem cell transplantation with carfilzomib, lenalidomide and dexamethasone or lenalidomide.

1:15 PM – 2:15 PM EEST

P-398: Dynamic immune response in multiple myeloma patients infected with SARS-CoV-2 Omicron BA.4/5 subvariant in China

1:15 PM – 2:15 PM EEST

P-399: Isatuximab Promotes Immune Activation in the Bone Marrow Microenvironment of Patients with High Risk Smoldering Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-400: An immune atlas of the dysfunctional cellular and antibody response to COVID-19 vaccination in patients with multiple myeloma

1:15 PM – 2:15 PM EEST

P-401: miRNA-seq and clinical validation of miR-221/222 cluster in multiple myeloma

1:15 PM – 2:15 PM EEST

P-402: Inhibition of proline production by stromal cells negatively impacts myeloma tumor growth by reducing cytokine and growth factor secretion.

1:15 PM – 2:15 PM EEST

P-403: Identification and quantification of novel circular RNAs (circRNAs) deriving from the apoptosis-related BCL2L12 gene in multiple myeloma cells, using targeted nanopore sequencing and nested qPCR

1:15 PM – 2:15 PM EEST

P-404: Single-Cell Profiling Reveals Inflammaging-Associated Dysregulations in Rapidly Progressing Multiple Myeloma Patients

1:15 PM – 2:15 PM EEST

P-405: ISOTYPE MATCHED IMMUNOPARESIS COULD HELP IN PREDICTING PROGRESSION TO MULTIPLE MYELOMA IN MGUS PATIENTS

1:15 PM – 2:15 PM EEST

P-406: Development of a 3D bioreactor model using a perfusion bioreactor to study osteocyte progenitor cells and the Involvement of single ECM molecules in Multiple Myeloma Bone Disease

1:15 PM – 2:15 PM EEST

P-407: 3D organoid model: Using primary cells to study therapeutic effects on patients’ myeloma tumor niche

1:15 PM – 2:15 PM EEST

P-408: Differential peripheral cytokine profile and tumor microenvironment in patients with or without a history of BCMA-directed therapy prior to elranatamab: Analysis of MagnetisMM-3

1:15 PM – 2:15 PM EEST

P-409: Elevated LAG-3 expression in plasma cells and lymphoid subpopulations at distinct stages of Multiple Myeloma disease progression

1:15 PM – 2:15 PM EEST

P-411: Large-scale single-cell dissection of immune dysregulation in patients with monoclonal gammopathies

1:15 PM – 2:15 PM EEST

P-412: Loss of 3’U-tRFHisGTG in predicting poor survival and treatment outcome in multiple myeloma

1:15 PM – 2:15 PM EEST

P-413: Inflammatory markers characterize neutrophils and C1q+ TAMs in the day 100 bone marrow aspirate post ASCT of patients with early progression

1:15 PM – 2:15 PM EEST

P-414: Single-Cell Profiling Reveals Aggressive Tumor Subcluster and Compromised Immune State in Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-415: Profiling of patient bone marrow adipocytes in the myeloma microenvironment

1:15 PM – 2:15 PM EEST

P-416: Immunophenotypic profile defines cytogenetic stability and unveils distinct prognoses in patients with newly-diagnosed multiple myeloma (NDMM)

1:15 PM – 2:15 PM EEST

P-417: SKY92 gene expression profiling and cytogenetics according to R2-ISS for multiple myeloma risk classification

1:15 PM – 2:15 PM EEST

P-418: The metabolic profile of multiple myeloma

1:15 PM – 2:15 PM EEST

P-419: Demographics, Clinical Features and Treatment Outcomes of Waldenstrom Macroglobulinemia from a Tertiary Care Cancer Centre in India.

1:15 PM – 2:15 PM EEST

P-420: Unusual Presentations of Amyloidosis: A Multicase Analysis Highlighting Diverse Clinical Manifestations and Diagnostic Challenges

1:15 PM – 2:15 PM EEST

P-421: Reference interval of free light chain ratio for patients in chronic hemodialysis

1:15 PM – 2:15 PM EEST

P-422: Impact of early response and CXCR4 mutation status on progression-free survival with ibrutinib-based therapy in Waldenström macroglobulinemia: A post hoc analysis of the iNNOVATE trial

1:15 PM – 2:15 PM EEST

P-423: Partial response or better at 6 months is not a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with zanubrutinib: a post hoc analysis of the ASPEN study

1:15 PM – 2:15 PM EEST

P-424: Partial response or better at 6 months is not shown to be a prognostic indicator of progression-free survival in Waldenström macroglobulinemia treated with acalabrutinib: A post hoc analysis

1:15 PM – 2:15 PM EEST

P-425: CARDIAC AL AMYLOIDOSIS EXPERIENCED IN THE LAST DECADE FROM A SINGLE CENTER

1:15 PM – 2:15 PM EEST

P-426: Thrombotic and bleeding complications in patients with AL amyloidosis

1:15 PM – 2:15 PM EEST

P-427: Smoldering multiple myeloma associated with a acquired von Willebrand syndrome , successfully treated by daratumumab, lenalidomide and dexamethasone

1:15 PM – 2:15 PM EEST

P-428: Clinicopathological profile and treatment outcomes in patients with monoclonal gammopathy of renal significance (MGRS): a single centre experience

1:15 PM – 2:15 PM EEST

P-429: Real-world data of zanubrutinib treatment for patients with previously treated Waldenstrom Macroglobulinemia

1:15 PM – 2:15 PM EEST

P-430: INCIDENCE OF PRIMARY PLASMA CELL LEUKEMIA WITH THE NEW DIAGNOSTIC CRITERIA.

1:15 PM – 2:15 PM EEST

P-431: Clinical characteristics, prognostic factors and treatment outcomes in patients diagnosed with primary plasma cell leukemia based on the revised criteria (KMM2204)

1:15 PM – 2:15 PM EEST

P-432: NASOPHARYNGEAL PLASMACYTOMA WİTH TUMEFACTİVE AMYLOİDOSİS ("AMYLOİDOMA") PRESENTİNG WITH UNİLATERAL HEARİNG LOSS

1:15 PM – 2:15 PM EEST

P-433: Targeting Free Light Chain Secretion Via Botulinum Neurotoxin Is a Novel Therapeutic Strategy in AL Amyloidosis By Inducing a Terminal Unfolded Protein Response

1:15 PM – 2:15 PM EEST

P-434: A Patient with CD20-positive Small Cell Variant Plasma Cell Myeloma Misdiagnosed as Lymphoplasmacytic Lymphoma

1:15 PM – 2:15 PM EEST

P-435: Acquired angioedema, a rare manifestation of MGCS

1:15 PM – 2:15 PM EEST

P-436: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Patients with Amyloid Light Chain (AL) Amyloidosis

1:15 PM – 2:15 PM EEST

P-437: Minor Salivary Gland Biopsy versus Bone Marrow Biopsy for the diagnosis of Amyloidosis AL: a comparative retrospective study

1:15 PM – 2:15 PM EEST

P-438: Castleman disease: histopathologic reclassification, clinical characteristics and endpoints in a reference center in Mexico

1:15 PM – 2:15 PM EEST

P-439: Identifying early suboptimal haematological response in patients with AL amyloidosis treated with bortezomib-based chemotherapy

1:15 PM – 2:15 PM EEST

P-440: Validation of second revision of international staging system (R2 ISS) in a real-world myeloma population – an Asia Pacific Myeloma and Related Diseases Registry (APAC MRDR) study

1:15 PM – 2:15 PM EEST

P-441: Soluble Urokinase Plasminogen Activator Receptor (SuPAR) in patients with plasma cell dyscrasias, a pilot study

1:15 PM – 2:15 PM EEST

P-442: Imaging Cardiac Amyloidosis using 18F-Florbetaben Positron Electron Topography (PET) in Systemic Light Chain (AL) Amyloidosis.

1:15 PM – 2:15 PM EEST

P-443: Localised Light Chain (AL) Amyloidosis: Presentation, Treatment and Outcomes; an Observational Study.

1:15 PM – 2:15 PM EEST

P-444: A comparison of immunohistochemistry and laser microdissection tandem mass spectrometry to identify the amyloid fibril protein from formalin-fixed paraffin embedded biopsy samples.

1:15 PM – 2:15 PM EEST

P-445: Optimisation of laser capture microdissection with tandem mass spectrometry for the diagnosis of amyloid subtype.

1:15 PM – 2:15 PM EEST

P-446: Waldenström Macroglobulinaemia lymphoma patients have impaired platelet haemostatic function

1:15 PM – 2:15 PM EEST

P-447: Daratumumab based Induction for Plasma cell leukaemia & early ASCT: Experience from a tertiary care hospital in North India

1:15 PM – 2:15 PM EEST

P-448: Impact of Molecular Cytogenetic Abnormalities on the Risk of Disease Progression in Solitary Bone Plasmacytomas

1:15 PM – 2:15 PM EEST

P-449: Role of Education and Empowerment in Multiple Myeloma patients

1:15 PM – 2:15 PM EEST

P-450: Comparison of a battery powered device (OnControl) versus manual Jamshidi needle for bone marrow biopsy in adult patients with plasma cell disorders: A prospective randomized control trial (RCT)

1:15 PM – 2:15 PM EEST

P-451: Association between Dexamethasone Exposure and Visually Significant Cataracts in Myeloma

1:15 PM – 2:15 PM EEST

P-452: Financial Toxicity and Time Toxicity among Patients with Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-453: Randomized Phase II Study of Digital Life Coaching during Stem Cell Transplantation for Myeloma

1:15 PM – 2:15 PM EEST

P-454: Patients views on the relevance of Quality of Life (QoL) Questionnaires commonly applied to evaluate the QoL of patients with AL Amyloidosis

1:15 PM – 2:15 PM EEST

P-455: Survey of Multiple Myeloma (MM) patients and Healthcare Professionals (HCPs) on the relevance of existing Health Quality-of-Life (QoL) Questionnaires (QoLQ) to real-world QoL issues of MM patients

1:15 PM – 2:15 PM EEST

P-456: Survey on real world Quality of Life (QoL) issues relevant to distinct AL Amyloidosis patient subgroups

1:15 PM – 2:15 PM EEST

P-457: Waldenstrom’s Macroglobulinaemia (WM) patients’ online survey -Currently available QoLQs not representative of Real-world Health Quality-of-Life (QoL) issues of WM patients

1:15 PM – 2:15 PM EEST

P-458: The impact of continuous therapy on the Quality of Life in Romanian patients with Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-459: A Randomized, Controlled Phase 2 Trial of Uproleselan, an E-Selectin Inhibitor, vs Placebo to Reduce GI Toxicity in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

1:15 PM – 2:15 PM EEST

P-460: Evaluation of a precision-based exercise program for patients with Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-461: An overview of challenges experienced in multiple myeloma: perspectives of hematologist-oncologists and specialist nurses

1:15 PM – 2:15 PM EEST

P-462: Free Light Chain Ratio over 100 and Risk of Hemodialysis in Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-463: Patient Characteristics and Burden in Lenalidomide Refractory Multiple Myeloma Patients in Europe: A Real-World Survey

1:15 PM – 2:15 PM EEST

P-464: Treatment Decision-Making in Patients Diagnosed With Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-465: Global Disparities in Multiple Myeloma: Examining Adverse Events and Drug Toxicity Trends

1:15 PM – 2:15 PM EEST

P-466: PERIPHERAL AND SEVERE AUTONOMIC NEUROPATHY CHARACTERIZED BY DIZZINESS, ORTHOSTATIC HYPOTENSION AND WEIGHT LOSS CAUSED BY BORTEZOMIB.

1:15 PM – 2:15 PM EEST

P-467: Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse National Health and Nutrition Examination Survey (NHANES) case-control study

1:15 PM – 2:15 PM EEST

P-468: Risk of Secondary Primary Malignancies after Multiple Myeloma in the Novel Therapy Era : A Nationwide Case-Control Cohort Study

1:15 PM – 2:15 PM EEST

P-469: Observational study of COVID-19 prophylactic antibody (Tixagevimab/Cilgavimab) administration for multiple myeloma patients

1:15 PM – 2:15 PM EEST

P-470: Single center experience of denosumab for hypercalcemia in multiple myeloma

1:15 PM – 2:15 PM EEST

P-471: The MMRF Cure Cloud research study: a real-world longitudinal investigation of patient treatments and outcomes, including Patient Reported Outcome (PRO) surveys

1:15 PM – 2:15 PM EEST

P-472: Evaluation of the usefulness of the QuantiFERON-TB Gold In-Tube test for the detection of latent Mycobacterium tuberculosis infections in patients underwent autologous stem cell transplantation

1:15 PM – 2:15 PM EEST

P-473: Real-world evidence of Statins and Oral Antidiabetics for Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-474: The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to BCMA-Directed Therapies: Results from the MagnetisMM-3 Study

1:15 PM – 2:15 PM EEST

P-475: Are we downplaying toxicity with our choice of words? A systematic review of randomized myeloma trials.

1:15 PM – 2:15 PM EEST

P-476: More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial

1:15 PM – 2:15 PM EEST

P-477: PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA IN THE OMICRON SARS-COV-2 ERA

1:15 PM – 2:15 PM EEST

P-478: Humanistic, Clinical, and Economic Burden in Patients with Relapsed or Refractory Multiple Myeloma on Second Line or Higher Therapy: A Systematic Literature Review

1:15 PM – 2:15 PM EEST

P-479: Disparities in Clinical Trial Enrolment and Survival Outcomes by Socio-economic Class in Multiple Myeloma

1:15 PM – 2:15 PM EEST

P-480: Outcome of Pneumocystis jirovecii pneumonia in patients with multiple myeloma

1:15 PM – 2:15 PM EEST

P-481: The effect of touch on pain, anxiety and the patient experience during bone marrow biopsies

1:15 PM – 2:15 PM EEST

P-482: Dietary habits correlate with myeloma pathogenesis and treatment outcome in multiple myeloma

1:15 PM – 2:15 PM EEST

P-483: A Whole Foods Plant-based Weight Loss Intervention Improves Metabolic and Immune Biomarkers in MGUS/SMM Patients as well as Progression Trajectory in a Subset – The NUTRIVENTION Trial

1:15 PM – 2:15 PM EEST

P-484: Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias.

1:15 PM – 2:15 PM EEST

P-485: Novel Observation of the Negative Effects of Persistent Chronic Opioid Use on Myeloma Survival: A Retrospective Urban-Based Cohort Study and Ongoing Prospective HealthTree Survey Study

1:15 PM – 2:15 PM EEST

P-486: Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma

1:15 PM – 2:15 PM EEST

P-487: Adherence to patient-reported symptom monitoring and subsequent clinical interventions for patients with Multiple Myeloma in outpatient care:
A longitudinal observational study

1:15 PM – 2:15 PM EEST

P-488: Expert in the Loop - AI assisted generation of Real-World-Evidence

1:15 PM – 2:15 PM EEST

P-489: Prolonged cytopenia after CAR T-cell therapy in multiple myeloma: results from a prospective comprehensive biomarker study

1:15 PM – 2:15 PM EEST

P-490: Genetic Alterations In Multiple Myeloma With Extramedullary Disease

1:15 PM – 2:15 PM EEST

P-491: Ratio of NK cells expressingNKG2A or not (NKG2A+pos/NKG2A-neg) is associated with post-transplant remission period for myeloma patients who have received autologous transplantation